Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AT-211
- Development stage
- Unknown
- Lead developer
- AbTis
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AT-211 is an immune-stimulating antibody conjugate (ISAC) developed by AbTis, utilizing their proprietary AbClick site-specific conjugation technology. It consists of an antibody conjugated to a Toll-like receptor 9 (TLR9) agonist payload. The drug is designed to selectively deliver the TLR9 agonist to the tumor microenvironment, thereby activating innate immune cells and inducing a robust anti-tumor immune response while minimizing systemic toxicity. By using the AbClick platform, AbTis can achieve precise drug-to-antibody ratios (DAR) without the need for antibody engineering. As of early 2024, the program is in Phase I clinical development for the treatment of solid tumors.
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on AT-211.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AT-211.